In support of our report, Timmermans-Sprang et al found inhibition of the PI3K/mTOR pathway in breast cancer was associated with enhanced expression of β-catenin and EGFR, implying that enhanced EGFR may function as a key signaling intermediate of β-catenin nuclear accumulation [41]. This evidence concerns the gene EGFR and breast cancer.